NRX Pharmaceuticals
Open
$3.08
Prev. Close
$3.08
High
$3.09
Low
$3.08
Market Snapshot
$86.82M
-3.0
-2.41
29
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is headquartered in Wilmington, Delaware. The company went IPO on 2017-11-20. The company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.
emptyResult
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is headquartered in Wilmington, Delaware. The company went IPO on 2017-11-20. The company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.
Recently from Cashu
Ketamine Revolutionizes Mental Health Treatment: NRX Pharmaceuticals Positioned for Growth
Shifting Perspectives: Ketamine's Promising Role in Mental Health Treatment Ketamine, traditionally known for its use as an anesthetic, is experiencing a significant transformation in its application…
NRX Pharmaceuticals and Ketamine: Transforming Approaches to Mental Health Treatment
Shifting Paradigms: Ketamine's Role in Mental Health Treatment NRX Pharmaceuticals stands at the forefront of a growing movement that highlights ketamine's transformative potential in mental health tr…
NRX Pharmaceuticals: Summary of Recent Developments and Future Outlook
Please provide the content you would like me to summarize, and I will create a 300-word article for you.
NRX Pharmaceuticals: Key Developments and Future Outlook in the Biopharmaceutical Sector
Please provide the content you would like me to summarize, and I will create a 300-word article for you.